mRNA shingles candidate BNT-166 signals BioNTech’s broader vaccine push

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 9:04 PM ET. Details in the imprint.

BioNTech’s mRNA shingles vaccine candidate BNT-166 has become one of the company’s key post-COVID development projects, designed to prevent herpes zoster by encoding multiple antigens of the varicella-zoster virus and leveraging the same mRNA platform used in its blockbuster COVID-19 vaccine.

How BNT-166 fits into BioNTech’s mRNA playbook

BNT-166 is part of BioNTech’s infectious-disease portfolio, which the company highlights alongside programs for influenza, malaria and tuberculosis as it works to turn its mRNA know-how into a broader vaccine franchise beyond SARS-CoV-2. According to BioNTech’s latest pipeline overview, BNT-166 is an mRNA-based herpes zoster candidate being developed to address shingles in adults at risk of reactivation of latent varicella-zoster virus, using lipid nanoparticle-formulated mRNA to trigger robust cellular and humoral immune responses against several viral targets. BioNTech’s official pipeline overview describes BNT-166 as a shingles vaccine program within its prophylactic infectious-disease segment.

Shingles is caused by reactivation of varicella-zoster virus, typically years after a primary chickenpox infection, and is associated with painful dermatomal rashes and potential complications such as postherpetic neuralgia, particularly in older adults and immunocompromised patients. Existing vaccines based on adjuvanted protein subunits have set a high efficacy bar, so BioNTech’s strategy with BNT-166 focuses on using mRNA to express multiple viral glycoproteins in a way that may drive strong CD4+ and CD8+ T-cell responses alongside neutralizing antibodies, aiming for durable protection and potentially more flexible manufacturing compared with traditional recombinant approaches.

The shingles candidate sits alongside other infectious-disease projects where BioNTech is trying to demonstrate that mRNA platforms can be tuned disease by disease, adjusting antigen selection, mRNA design and lipid nanoparticle formulations while keeping a scalable manufacturing backbone that proved itself during the COVID-19 pandemic. In public presentations, management has framed BNT-166 as part of a second wave of commercial opportunities that could start contributing to revenue later in the decade if pivotal data are positive and regulators are satisfied with safety and durability outcomes.

From a strategic perspective, BNT-166 is important because it targets an established, premium adult-vaccine market where payers are already familiar with the burden of disease and the cost of complications, which can support pricing for high-efficacy, multi-dose regimens in older populations. Market analysts covering vaccines point out that shingles is viewed as one of the more attractive non-pediatric opportunities given aging demographics in the United States, Europe and parts of Asia, and mRNA entrants such as BNT-166 would be evaluated against incumbent protein-based vaccines on endpoints including efficacy versus placebo, comparative immunogenicity and the tolerability profile, especially reactogenicity in older adults.

BioNTech positions its infectious-disease candidates, including shingles, as a way to reduce dependence on volatile COVID-19 demand by building a more stable, recurrent revenue base anchored in routine vaccination and adult booster programs. In recent quarterly communications, the company has emphasized that resources generated from its COVID-19 collaboration are being invested into late-stage oncology programs and into a diversified vaccine portfolio that features candidates like BNT-166 in addition to flu and combined respiratory shots, in line with its stated goal of having multiple non-COVID products on the market over the medium term. Recent BioNTech investor communications underscore that infectious-disease programs are a key pillar of its post-pandemic strategy.

For investors, BNT-166 is one example of how BioNTech is trying to translate its mRNA technology into durable adult-vaccine franchises while oncology candidates progress in parallel, with shingles offering a clearly defined clinical path and a competitive landscape dominated so far by protein-based vaccines from established pharmaceutical players. Shares of BioNTech SE (US09075V1026) traded on NASDAQ at $87.15 on 06/13/2026.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.